Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Blanco, C; Garcia-Alfonso, P; Robles, L; Gravalos, C; Rueda, D; Martinez, J; Pachon, V; Longo, F; Martinez, V; Iglesias, I; Salvador, S; Sanjurjo, M; Lopez-Fernandez, LA.

Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity

PHARMACOGENOMICS. 2017; 18(13): 1215-1223 Nº de citas: 11 [doi:10.2217/pgs-2017-0118]

Provencio, M; Rodriguez, M; Cantos, B; Sabin, P; Quero, C; Garcia-Arroyo, FR; Rueda, A; Maximiano, C; Rodriguez-Abreu, D; Sanchez, A; Silva, J; Garcia, V.

mRNA in exosomas as a liquid biopsy in non-Hodgkin Lymphoma: a multicentric study by the Spanish lymphoma oncology group

Oncotarget. 2017; 8(31): 50949-50957 Nº de citas: 39 [doi:10.18632/oncotarget.16435]

Jimenez-Fonseca, P; Carmona-Bayonas, A; Calderon, C; Boj, JF; Font, C; Lecumberri, R; Monreal, M; Martin, AJM; Otero, R; Rubio, A; Ruiz-Artacho, P; Fernandez, CS; Colome, E; Segura, PP.

FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(8): 997-1009 Nº de citas: 10 [doi:10.1007/s12094-017-1632-3]

Davies, MA; Saiag, P; Robert, C; Grob, JJ; Flaherty, KT; Arance, A; Chiarion-Sileni, V; Thomas, L; Lesimple, T; Mortier, L; Moschos, SJ; Hogg, D; Marquez-Rodas, I; Del Vecchio, M; Lebbe, C; Meyer, N; Zhang, Y; Huang, YJ; Mookerjee, B; Long, GV.

Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

LANCET ONCOLOGY. 2017; 18(7): 863-873 Nº de citas: 583 [doi:10.1016/S1470-2045(17)30429-1]

Mendizabal, E; De Leon-Luis, J; Gomez-Hidalgo, NR; Joigneau, L; Pintado, P; Rincon, P; Ortega, V; Lizarraga, S.

Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY. 2017; 214: 131-139 Nº de citas: 14 [doi:10.1016/j.ejogrb.2017.04.023]

Prat, A; Lluch, A; Turnbull, AK; Dunbier, AK; Calvo, L; Albanell, J; de la Haba-Rodriguez, J; Arcusa, A; Chacon, JI; Sanchez-Rovira, P; Plazaola, A; Munoz, M; Pare, L; Parker, JS; Ribelles, N; Jimenez, B; Bin Aiderus, AA; Caballero, R; Adamo, B; Dowsett, M; Carrasco, E; Martin, M; Dixon, JM; Perou, CM; Alba, E.

A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse

CLINICAL CANCER RESEARCH. 2017; 23(12): 3035-3044 Nº de citas: 41 [doi:10.1158/1078-0432.CCR-16-2092]

Custodio, A; Carmona-Bayonas, A; Jimenez-Fonseca, P; Sanchez, ML; Viudez, A; Hernandez, R; Cano, JM; Echavarria, I; Pericay, C; Mangas, M; Visa, L; Buxo, E; Garcia, T; Palomo, AR; Mancenido, FA; Lacalle, A; Macias, I; Azkarate, A; Ramchandani, A; Montes, AF; Lopez, C; Longo, F; Bayona, RS; Limon, ML; Diaz-Serrano, A; Hurtado, A; Madero, R; Gomez, C; Gallego, J.

Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab

BRITISH JOURNAL OF CANCER. 2017; 116(12): 1526-1535 Nº de citas: 48 [doi:10.1038/bjc.2017.122]

Hidalgo, M; Alvarez, R; Gallego, J; Guillen-Ponce, C; Laquente, B; Macarulla, T; Munoz, A; Salgado, M; Vera, R; Adeva, J; Ales, I; Arevalo, S; Blazquez, J; Calsina, A; Carmona, A; de Madaria, E; Diaz, R; Diez, L; Fernandez, T; de Paredes, BG; Gallardo, ME; Gonzalez, I; Hernando, O; Jimenez, P; Lopez, A; Lopez, C; Lopez-Rios, F; Martin, E; Martinez, J; Martinez, A; Montans, J; Pazo, R; Plaza, JC; Peiro, I; Reina, JJ; Sanjuanbenito, A; Yaya, R; Carrato, A.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(6): 667-681 Nº de citas: 22 [doi:10.1007/s12094-016-1594-x]

Pellicer, M; Garcia-Gonzalez, X; Garcia, MI; Robles, L; Gravalos, C; Garcia-Alfonso, P; Pachon, V; Longo, F; Martinez, V; Blanco, C; Iglesias, I; Sanjurjo, M; Lopez-Fernandez, LA.

Identification of new SNPs associated with severe toxicity to capecitabine

PHARMACOLOGICAL RESEARCH. 2017; 120: 133-137 Nº de citas: 43 [doi:10.1016/j.phrs.2017.03.021]

Gonzalez-Cao, M; Arance, A; Piulats, JM; Marquez-Rodas, I; Manzano, JL; Berrocal, A; Crespo, G; Rodriguez, D; Perez-Ruiz, E; Berciano, M; Soria, A; Castano, AG; Espinosa, E; Montagut, C; Alonso, L; Puertolas, T; Aguado, C; Royo, MA; Blanco, R; Rodriguez, JF; Munoz, E; Mut, P; Barron, F; Martin-Algarra, S; Spanish Melanoma Grp.

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

CLINICAL & TRANSLATIONAL ONCOLOGY. 2017; 19(6): 761-768 Nº de citas: 8 [doi:10.1007/s12094-016-1602-1]

Aapro, M; De Laurentiis, M; Rea, D; Rocha, JEB; Elizalde, R; Landherr, L; Linderholm, B; Mamounas, E; Markopoulos, C; Neven, P; Petrovsky, A; Rouzier, R; Smit, V; Svedman, C; Schneider, D; Thomssen, C; Martin, M.

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

BREAST. 2017; 33: 191-199 Nº de citas: 4 [doi:10.1016/j.breast.2017.01.012]

Provencio, M; Sabin, P; Gomez-Codina, J; Torrente, M; Calvo, V; Llanos, M; Guma, J; Quero, C; Blasco, A; Cruz, MA; Aguiar, D; Garcia-Arroyo, F; Lavernia, J; Martinez, N; Morales, M; Saez-Cusi, A; Rodriguez, D; de la Cruz, L; Sanchez, JJ; Rueda, A; GOTEL Spanish Lymphoma Oncology Gr.

Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry

PLoS One. 2017; 12(5): Nº de citas: 20 [doi:10.1371/journal.pone.0177204]

del Alba, AG; Arranz, JA; Puente, J; Mendez-Vidal, MJ; Gallardo, E; Grande, E; Perez-Valderrama, B; Gonzalez-Billalabeitia, E; Lazaro-Quintela, M; Pinto, A; Lainez, N; Piulats, JM; Esteban, E; Rey, JPM; Garcia, JA; Suarez, C.

Recent advances in genitourinary tumors: A review focused on biology and systemic treatment

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017; 113: 171-190 Nº de citas: 20 [doi:10.1016/j.critrevonc.2017.03.010]

Puente, J; Grande, E; Medina, A; Maroto, P; Lainez, N; Arranz, JA.

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

Therapeutic Advances in Medical Oncology. 2017; 9(5): 307-318 Nº de citas: 49 [doi:10.1177/1758834017692779]

Jimenez-Fonseca, P; Carmona-Bayonas, A; Lorenzo, MLS; Plazas, JG; Custodio, A; Hernandez, R; Garrido, M; Garcia, T; Echavarria, I; Cano, JM; Palomo, AR; Mangas, M; Declara, IM; Ramchandani, A; Visa, L; Viudez, A; Buxo, E; Diaz-Serrano, A; Lopez, C; Azkarate, A; Longo, F; Castanon, E; Bayona, RS; Pimentel, P; Limon, ML; Cerda, P; Llosa, RA; Serrano, R; Lobera, MPF; Alsina, M; Nuno, A; Gomez-Martin, C.

Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

Gastric Cancer. 2017; 20(3): 465-474 Nº de citas: 18 [doi:10.1007/s10120-016-0639-8]

Garcia-Donas, J; Font, A; Perez-Valderrama, B; Virizuela, JA; Climent, MA; Hernando-Polo, S; Arranz, JA; Llorente, MD; Lainez, N; Villa-Guzman, JC; Mellado, B; del Alba, AG; Castellano, D; Gallardo, E; Anido, U; del Muro, XG; Domenech, M; Puente, J; Morales-Barrera, R; Perez-Gracia, JL; Bellmunt, J.

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

LANCET ONCOLOGY. 2017; 18(5): 672-681 Nº de citas: 45 [doi:10.1016/S1470-2045(17)30242-5]

Gonzalez-Billalabeitia, E; Sepulveda, JM; Maroto, P; Aparicio, J; Arranz, JA; Esteban, E; Girones, R; Lopez-Brea, M; Mendez-Vidal, MJ; Pinto, A; Sastre, J; de Prado, DS; Terrasa, J; Vazquez, S; Powles, T; Beyer, J; Castellano, D; del Muro, XG; Spanish Germ Cell Canc Grp; Spanish Oncology Genitourinary Grp.

Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer

European Urology Focus. 2017; 3(2-3): 280-286 [doi:10.1016/j.euf.2016.07.002]

Climent, MA; Torregrosa, MD; Vazquez, S; Girones, R; Arranz, JA.

Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?

CANCER TREATMENT REVIEWS. 2017; 55: 173-180 Nº de citas: 4 [doi:10.1016/j.ctrv.2017.03.007]